Merck & Company Inc (MRK)vsVanda Pharmaceuticals Inc (VNDA)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
VNDA
Vanda Pharmaceuticals Inc
$7.10
+0.71%
HEALTHCARE · Cap: $411.32M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 29983% more annual revenue ($65.01B vs $216.10M). MRK leads profitability with a 28.1% profit margin vs -102.0%. VNDA appears more attractively valued with a PEG of 2.23. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
VNDA
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Margin of Safety
+84.8%
Fair Value
$40.21
Current Price
$7.10
$33.11 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Reasonable price relative to book value
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Expensive relative to growth rate
Smaller company, higher risk/reward
ROE of -50.9% — below average capital efficiency
Earnings declined 95.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : VNDA
The strongest argument for VNDA centers on Price/Book.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : VNDA
The primary concerns for VNDA are PEG Ratio, Market Cap, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while VNDA is a turnaround play — different risk/reward profiles.
VNDA carries more volatility with a beta of 0.71 — expect wider price swings.
VNDA is growing revenue faster at 7.6% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 39/100), backed by strong 28.1% margins. VNDA offers better value entry with a 84.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Vanda Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company is headquartered in Washington, the District of Columbia.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?